Anti-leukotriene agents in modern therapy of bronchial asthma in children
https://doi.org/10.21518/2079-701X-2020-1-134-138
Abstract
The article highlights the present-day knowledge on the role of leukotrienes in the pathogenesis of allergic diseases of respiratory tract such as bronchial asthma in children. It presents the mechanisms of action that determine the points of application and recommended indications for use of Montelukast, a leukotriene receptor antagonist. The clinical trials showed its efficacy and safety in children of 2 years and over. Montelukast is used to prevent daytime and night-time symptoms of bronchial asthma, bronchospasm caused by physical exertion and cold air, treat bronchial asthma in patients with hypersensitivity to acetylsalicylic acid, known as aspirin asthma, improve the daytime and night-time symptoms of seasonal and/or year-round allergic rhinitis in children. Montelukast is effective in bronchial asthma caused by viral, specifically rhinovirus, infections, and in bronchial asthma combined with allergic rhinitis. It can be successfully used as monotherapy in mild bronchial asthma. If situation requires to strengthen the baseline therapy in moderate and severe bronchial asthma, the alternative to increasing the dose of inhaled glucocorticosteroids would be addition of Montelukast to the complex therapy. The drug is well tolerated, side effects are quite rare. It must be admitted that today anti-leukotriene agents have filled a specific market niche in the treatment of bronchial asthma and allergic rhinitis in children, have showed their clinical efficacy, especially in certain phenotypes of the disease, which proves that they would become widely used in the near future.
About the Author
Yu. L. Mizernitskiy
Veltischev Research and Clinical Institute for Pediatrics of Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Yuriy L. Mizernitskiy - Dr. of Sci. (Med.), Professor, Honoured Healthcare Worker of the Russian Federation, Head of Department of Chronic Inflammatory and Allergic Lung Diseases, Autonomous Structural Subdivision “Veltischev Research and Clinical Institute for Pediatrics“.
2, Taldomskaya St., Moscow, 125412.
References
1. Batozhargalova B.T., Mizernitsky Y.L., Podolnaya M.A. Meta-analysis of the prevalence of asthma-like symptoms and asthma in Russia (according to the results of ISAAC). Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics). 2016;61(4):59–69. (In Russ.) doi: 10.21508/1027-4065-2016-61-4-59-69.
2. Ilina N.I., Kurbacheva O.M., Pavlova K.S., Polner S.A. Federal Clinical Recommendations. Allergic rhinitis. Rossiyskiy Allergologicheskiy Zhurnal = Russian Journal of Allergy. 2018;15(4):43–53. (In Russ.) Available at: http://rusalljournal.ru/sc/pdf/4-2018.pdf.
3. Sulaymanov Sh.A., Muratova Zh.K. Epidemiology and comorbidity of allergic diseases in children. In: Mizernitskiy Yu. L. (ed.) Pediatric pulmo nology: problems and solutions. Issue 16. Moscow: Medpractika-M; 2016. pp. 179–181. (In Russ.) Available at: https://www.books-up.ru/ru/excerpt/pulmonologiya-detskogo-vozrasta-problemy-i-resheniya-vyp-16-3819057/?page=7.
4. Kaganov S.Yu. (ed.). Bronchial asthma in children. М.: Meditsina; 1999. 368 p. (In Russ.)
5. Chuchalin A.G., Geppe N.A., Kolosova N.G., Kondyurina E.G., Malakhov A.B., Mizernitskiy Yu.L., Revyakina V.A. (eds.) National Program: Bronchial asthma in children. Treatment Strategy and Prevention. 5th ed. Moscow; 2017. 160 p. (In Russ.). Available at: http://astgmu.ru/wp-content/uploads/2018/10/Natsionalnaya-programma-BA-u-detej.-Strategiya-lecheniya-i-profilaktika.pdf.
6. Mizernitskiy Yu. L. Bronchial asthma. In: Rozinova N.N., Mizernitskiy Yu.L. (ed.). Chronic lung diseases in children. Moscow: Practica; 2011, pp. 149–168. (In Russ.)
7. Haq I., Harris C., Taylor J., McKean M.C., Brodlie M. Should we use montelukast in wheezy children? Arch Dis Child. 2017;102(11):997–998. doi: 10.1136/archdischild-2017-312655.
8. Mizernitskiy Yu. L. Key approaches to the treatment of bronchial asthma in children at the present stage. Pediatrics – suppl. Consilium Medicum. 2014;(4):25–27. (In Russ.)
9. Mizernitsky Y.L., Sulaimanov S.A. Antileukotriene drugs in modern pediatric practice. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2019;64(4):128–132. (In Russ.) doi: 10.21508/1027-4065-2019-64-4-128-132.
10. Csoma Z.1., Kharitonov S.A., Balint B., Bush A., Wilson N.M., Barnes P.J. Increased leukotrienes in exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med. 2002;(166):1345–1349. Available at: https://pediatrics.aappublications.org/content/112/Supplement_2/471.3.short.
11. Visitsunthorn N., Chirdjirapong V., Santadilog S., Pajarn P., Jirapongsananuruk O., Komoltri C., Vichyanon P. The effect of montelukast on bronchial hyperreactivity and lung function in asthmatic children aged 6–13 years. Asian Pac J Allergy Immunol. 2011;29(2):127–133. Available at: https://www.ncbi.nlm.nih.gov/pub-med/21980827.
12. Marinich V.V., Mizernitskiy Yu.L. Effort-induced bronchospasm in teenage athletes. In: Mizernitskiy Yu. L. (ed.) Pediatric pulmonology: problems and solutions. Issue 15. Moscow: Medpractika-M; 2016, pp. 217–221. (In Russ.) Available at: https://www.books-up.ru/excerpt/pulmonologiya-detskogo-vozrasta-problemy-i-resheniya-vyp-15-3668632/?page=1
13. Nagao M., Ikeda M., Fukuda N., Habukawa C., Kitamura T., Katsunuma T., Fujisawa T. LePAT (Leukotriene and Pediatric Asthma Translational Research Network) investigators. Early control treatment with montelukast in preschool children with asthma: A randomized controlled trial. Allergol Int. 2018;67(1):72–78. doi:10.1016/j.alit.2017.04.008.
14. Geppe N.A., Farber I.M. The use of montelukast, a leukotriene receptor antagonist, for the treatment of bronchial asthma in infants. Pul’monologiya = Russian pulmonology. 2009;(5):113–118. (In Russ.)
15. Mizernitsky Yu.L. Clinical significance of antileukotriene drugs in modern therapy of bronchial asthma in children. Ehffektivnaya farma koterapiya. Pediatriya = Effective Pharmacotherapy. Pediatrics. 2014;(3):16–18. (In Russ.) Available at: https://umedp.ru/articles/klinicheskoe_znachenie_antileykotrienovykh_preparatov_v_sovremennoy_terapii_bronkhialnoy_astmy_u_det.html.
16. Mizernitsky Y.L. Antileukotrienes in the treatment of bronchial asthma in children: expected and real success. Meditsinskiy sovet = Medical Council. (In Russ.) 2014;(14):46–49. doi: 10.21518/2079-701X-2014-14-46-49.
17. Barnes N. Effects of antileukotrienes in the treatment of asthma. Am J Respir Crit Care Med. 2000;(161):73–76. doi: 10.1164/ajrccm.161.supplement_1.ltta-15.
18. Bisgaard H., Zielen S., Garcia-Garcia M.L., Johnston S.L., Gilles L., Menten J., Tozzi C.A., Polos P. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med. 2005;171(4):315–322. doi: 10.1164/rccm.200407-894OC.
19. Knorr B., Franchi L.M., Bisgaard H. Montelukast, a leukotriene receptor antagonist, for the treatment of ent asthma in children aged 2 to 5 years. Pediatrics. 2001;108(3):E48. Available at: https://www.researchgate.net/publication/11813615_Montelukast_a_Leukotriene_Receptor_Antagonist_for_the_Treatment_of_Persistent_Asthma_in_Children_Aged_2_to_5_Years.
20. Scadding G.W., Scadding G.K. Recent advances in antileukotriene therapy. Curr Opin Allergy Clin Immunol. 2010;10(4):370–376. doi: 10.1097/ACI.0b013e32833bfa20.
21. Tenero L., Piazza M., Sandri M., Azzali A., Chinellato I., Peroni D., Boner A., Piacentini G. Effect of montelukast on markers of airway remodeling in children with asthma. Allergy Asthma Proc. 2016;37(5):77–83. doi: 10.2500/aap.2016.37.3978.
22. Wahn U., Dass S.B. Review of recent results of montelukast use as a monotherapy in children with mild asthma. Clin Ther. 2008;(30):1026–1035. doi: 10.1016/j.clinthera.2008.05.018.
23. Henderson W.R. Jr., Chiang G.K.S., Tien Y.-T., Chi E.Y. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med. 2006;173(7):718–728. doi: 10.1164/rccm.200501-088OC.
24. Pizzichini E., Leff J.A., Reiss T.F., Hendeles L., Boulet L.P., Wei L.X., Efthimiadis A.E., Zhang J., Hargreave F.E. Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial. Eur Respir J. 1999;14(1):12–18. doi: 10.1034/j.1399-3003.1999.14a04.x.
25. Knorr B., Matz J., Bernstein J.A. et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized trial. Pediatric Montelukast Study Group. JAMA. 1998;279(15):1181–1186. doi: 10.1001/jama.279.15.1181.
26. Massingham K., Fox S., Smaldone A. Asthma therapy in pediatric patients: a systematic review of treatment with montelukast versus inhaled corticosteroids. J Pediatr Health Care. 2014;28(1):51–62. doi: 10.1016/j.pedhc.2012.11.005.
27. Stanford R.H., Shah M., Chaudhari S.L. Clinical and economic outcomes associated with low-dose fluticasone propionate versus montelukast inchildren with asthma aged 4 to 11 years. Open Respir Med J. 2012;(6):37–43. doi: 10.2174/1874306401206010037.
28. Adelsberg J., Philip G., Pedinoff A.J., Meltzer E.O., Ratner P.H., Menten J. et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy. 2003;(58):1268–1276. doi: 10.1046/j.1398-9995.2003.00261.x.
29. Keskin O., Arik Yilmaz E., Motzkus C., Sackesen C., Lilly C.M., Kalayci O. The effect of montelukast on early-life wheezing: A randomized, double-blinded placebo-controlled study. Pediatr Allergy Immunol. 2018;29(1):50–57. doi: 10.1111/pai.12822.
30. Ducharme F.M., Bénard B. Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice. Eur Respir J. 2017;22;50(5). pii:1702135. doi: 10.1183/13993003.02135-2017.
31. Haarman M.G., van Hunsel F., de Vries T.W. Adverse drug reactions of montelukast in children and adults. Pharmacol Res Perspect. 2017;5(5). doi: 10.1002/prp2.341.
Review
For citations:
Mizernitskiy YL. Anti-leukotriene agents in modern therapy of bronchial asthma in children. Meditsinskiy sovet = Medical Council. 2020;(1):134-138. (In Russ.) https://doi.org/10.21518/2079-701X-2020-1-134-138
Views:
11707
Email this article 